Last reviewed · How we verify
YM 155
At a glance
| Generic name | YM 155 |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma (PHASE2)
- A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) (PHASE1, PHASE2)
- A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment (PHASE2)
- A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma (PHASE2)
- An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 (PHASE2)
- Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects (PHASE2)
- An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors (PHASE1, PHASE2)
- A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YM 155 CI brief — competitive landscape report
- YM 155 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI